Bortezomib: an effective agent in extramedullary disease in multiple myeloma
- 9 March 2006
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 76 (5), 405-408
- https://doi.org/10.1111/j.0902-4441.2005.t01-1-ejh2462.x
Abstract
Bortezomib is a potent and selective proteasome inhibitor recently introduced in the treatment of multiple myeloma (MM). This drug produces significant responses in about one-third of patients with relapsed/refractory disease. We first recognized the lack of efficacy of thalidomide in soft-tissue plasmacytomas. There is little information on the effect of bortezomib on extramedullary myeloma. Four of 23 patients treated with bortezomib at our institution had extramedullary involvement at the time of relapse. In three of these patients large soft-tissue plasmacytomas disappeared. This indicates that bortezomib may be useful in clinical situations of extramedullary disease in which other agents, such as thalidomide, may not be effective.Keywords
This publication has 21 references indexed in Scilit:
- The HOX-MEIS connection in AMLBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell lineThe Hematology Journal, 2004
- Prognostic value of angiogenesis in solitary bone plasmacytomaBlood, 2003
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple MyelomaLeukemia & Lymphoma, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998